{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:32:57Z","timestamp":1791937977985,"version":"4.3.4"},"reference-count":75,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T00:00:00Z","timestamp":1698537600000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.pcl.2022.07.006","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T17:37:10Z","timestamp":1667065030000},"page":"1181-1197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Hemolytic-Uremic Syndrome in Children"],"prefix":"10.1016","volume":"69","author":[{"given":"Olivia","family":"Boyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Niaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10095","key":"10.1016\/j.pcl.2022.07.006_bib1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pcl.2022.07.006_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"5","key":"10.1016\/j.pcl.2022.07.006_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1089\/fpd.2012.1401","article-title":"Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000-2010: epidemiologic features and comparison with E. coli O157 infections","volume":"10","author":"Gould","year":"2013","journal-title":"Foodborne Pathog Dis"},{"key":"10.1016\/j.pcl.2022.07.006_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fcimb.2020.00273","article-title":"Recent Updates on Outbreaks of Shiga Toxin-Producing Escherichia coli and Its Potential Reservoirs","volume":"10","author":"Kim","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"10.1016\/j.pcl.2022.07.006_bib5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/INF.0b013e3181993731","article-title":"Undercooked ground beef and person-to-person transmission as major risk factors for sporadic hemolytic uremic syndrome related to Shiga-toxin producing Escherchia coli infections in children in France","volume":"28","author":"Vaillant","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.pcl.2022.07.006_bib6","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1128\/IAI.00679-08","article-title":"Shiga toxin 2 targets the murine renal collecting duct epithelium","volume":"77","author":"Psotka","year":"2009","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.pcl.2022.07.006_bib7","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00467-010-1522-1","article-title":"Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction","volume":"25","author":"Zoja","year":"2010","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"12","key":"10.1016\/j.pcl.2022.07.006_bib8","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00467-018-4105-1","article-title":"Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS)","volume":"34","author":"Khalid","year":"2019","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"7","key":"10.1016\/j.pcl.2022.07.006_bib9","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2215\/CJN.08921209","article-title":"Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome","volume":"5","author":"Nathanson","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.pcl.2022.07.006_bib10","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-013631","article-title":"Severe acute neurologic involvement in children with hemolytic-uremic syndrome","volume":"147","author":"Brown","year":"2021","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.pcl.2022.07.006_bib11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s00467-018-3903-9","article-title":"Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study","volume":"33","author":"Percheron","year":"2018","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"26","key":"10.1016\/j.pcl.2022.07.006_bib12","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Complement blockade in severe shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9797","key":"10.1016\/j.pcl.2022.07.006_bib13","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0140-6736(11)61253-1","article-title":"Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial","volume":"378","author":"Greinacher","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pcl.2022.07.006_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamapediatrics.2016.2952","article-title":"Associations between hydration status, intravenous fluid administration, and outcomes of patients infected with shiga toxin-producing escherichia coli: a systematic review and meta-analysis","volume":"171","author":"Grisaru","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"1","key":"10.1016\/j.pcl.2022.07.006_bib15","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1542\/peds.100.1.e12","article-title":"Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections","volume":"100","author":"Bell","year":"1997","journal-title":"Pediatrics"},{"issue":"26","key":"10.1016\/j.pcl.2022.07.006_bib16","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJM200006293422601","article-title":"The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections","volume":"342","author":"Wong","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.pcl.2022.07.006_bib17","first-page":"357","article-title":"Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection","volume":"52","author":"Ikeda","year":"1999","journal-title":"Clin Nephrol"},{"issue":"11","key":"10.1016\/j.pcl.2022.07.006_bib18","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00467-007-0518-y","article-title":"Streptococcus pneumoniae-associated hemolytic uremic syndrome","volume":"23","author":"Copelovitch","year":"2008","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"2","key":"10.1016\/j.pcl.2022.07.006_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpeds.2007.04.057","article-title":"Hemolytic uremic syndrome and streptococcus pneumoniae: improving our understanding","volume":"151","author":"Geary","year":"2007","journal-title":"J\u00a0Pediatr"},{"issue":"9","key":"10.1016\/j.pcl.2022.07.006_bib20","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00467-019-04342-3","article-title":"New insights into the pathogenesis of Streptococcus pneumoniae-associated hemolytic uremic syndrome","volume":"35","author":"Scobell","year":"2020","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"2","key":"10.1016\/j.pcl.2022.07.006_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOP.0b013e32835d7f2c","article-title":"Update on Streptococcus pneumoniae associated hemolytic uremic syndrome","volume":"25","author":"Spinale","year":"2013","journal-title":"Curr Opin Pediatr"},{"issue":"4","key":"10.1016\/j.pcl.2022.07.006_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.semnephrol.2010.06.006","article-title":"Genetics and genetic testing in hemolytic uremic syndrome\/thrombotic thrombocytopenic purpura","volume":"30","author":"Noris","year":"2010","journal-title":"Semin Nephrol"},{"issue":"3","key":"10.1016\/j.pcl.2022.07.006_bib23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \"Kidney Disease: improving Global Outcomes\" (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.pcl.2022.07.006_bib24","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2215\/CJN.11830720","article-title":"Inherited kidney complement diseases","volume":"16","author":"Lemaire","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pcl.2022.07.006_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"10.1016\/j.pcl.2022.07.006_bib26","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00467-018-3933-3","article-title":"Extra-Renal manifestations of atypical hemolytic uremic syndrome in children","volume":"33","author":"Fidan","year":"2018","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"12","key":"10.1016\/j.pcl.2022.07.006_bib27","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9395","key":"10.1016\/j.pcl.2022.07.006_bib28","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/S0140-6736(03)14742-3","article-title":"Familial haemolytic uraemic syndrome and an MCP mutation","volume":"362","author":"Noris","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pcl.2022.07.006_bib29","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.ekir.2021.03.885","article-title":"Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality","volume":"6","author":"Ardissino","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1016\/j.pcl.2022.07.006_bib30","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin Nephrol"},{"issue":"6","key":"10.1016\/j.pcl.2022.07.006_bib31","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"issue":"8","key":"10.1016\/j.pcl.2022.07.006_bib32","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/sj.emboj.7601052","article-title":"Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome","volume":"25","author":"Jokiranta","year":"2006","journal-title":"EMBO J"},{"issue":"23","key":"10.1016\/j.pcl.2022.07.006_bib33","doi-asserted-by":"crossref","first-page":"15650","DOI":"10.1074\/jbc.M900814200","article-title":"Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome","volume":"284","author":"Lehtinen","year":"2009","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.pcl.2022.07.006_bib34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2249.2007.03574.x","article-title":"Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals","volume":"151","author":"Pickering","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.pcl.2022.07.006_bib35","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.pcl.2022.07.006_bib36","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2007-04-084533","article-title":"Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome","volume":"111","author":"Fang","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pcl.2022.07.006_bib37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00467-020-04714-0","article-title":"Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis","volume":"36","author":"Klambt","year":"2021","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"7","key":"10.1016\/j.pcl.2022.07.006_bib38","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1681\/ASN.2005010103","article-title":"Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome","volume":"16","author":"Kavanagh","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.pcl.2022.07.006_bib39","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1136\/jmg.2004.019083","article-title":"Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome","volume":"41","author":"Fremeaux-Bacchi","year":"2004","journal-title":"J\u00a0Med Genet"},{"issue":"4","key":"10.1016\/j.pcl.2022.07.006_bib40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/ki.2009.472","article-title":"Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome","volume":"77","author":"Bienaime","year":"2010","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.pcl.2022.07.006_bib41","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.pcl.2022.07.006_bib42","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1016\/j.pcl.2022.07.006_bib43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci United States America"},{"issue":"13","key":"10.1016\/j.pcl.2022.07.006_bib44","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2009-01-197640","article-title":"Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome","volume":"114","author":"Roumenina","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.pcl.2022.07.006_bib45","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.pcl.2022.07.006_bib46","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1093\/ndt\/gfq319","article-title":"Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation","volume":"25","author":"Loirat","year":"2010","journal-title":"Nephrol Dial Transpl"},{"issue":"23","key":"10.1016\/j.pcl.2022.07.006_bib47","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.pcl.2022.07.006_bib48","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.pcl.2022.07.006_bib49","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.pcl.2022.07.006_bib50","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.pcl.2022.07.006_bib51","first-page":"310","article-title":"Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome","volume":"10","author":"Macia","year":"2017","journal-title":"Clin Kidney J"},{"issue":"18","key":"10.1016\/j.pcl.2022.07.006_bib52","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pcl.2022.07.006_bib53","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.pcl.2022.07.006_bib54","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.pcl.2022.07.006_bib55","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.pcl.2022.07.006_bib56","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00467-018-4091-3","article-title":"Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use","volume":"34","author":"Wijnsma","year":"2019","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"5","key":"10.1016\/j.pcl.2022.07.006_bib57","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00467-019-4192-7","article-title":"Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way","volume":"34","author":"Ariceta","year":"2019","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"3","key":"10.1016\/j.pcl.2022.07.006_bib58","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00467-017-3813-2","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update","volume":"33","author":"Ardissino","year":"2018","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"8","key":"10.1016\/j.pcl.2022.07.006_bib59","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00467-019-04233-7","article-title":"Hemolytic uremic syndrome in a developing country: Consensus guidelines","volume":"34","author":"Bagga","year":"2019","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"6","key":"10.1016\/j.pcl.2022.07.006_bib60","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0022-3476(05)81967-5","article-title":"Cobalamin C defect associated with hemolytic-uremic syndrome","volume":"120","author":"Geraghty","year":"1992","journal-title":"J\u00a0Pediatr"},{"issue":"4","key":"10.1016\/j.pcl.2022.07.006_bib61","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/jimd.12012","article-title":"The clinical presentation of cobalamin-related disorders: From acquired deficiencies to inborn errors of absorption and intracellular pathways","volume":"42","author":"Huemer","year":"2019","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"5","key":"10.1016\/j.pcl.2022.07.006_bib62","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00467-016-3399-0","article-title":"Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity","volume":"32","author":"Beck","year":"2017","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"5","key":"10.1016\/j.pcl.2022.07.006_bib63","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.pcl.2022.07.006_bib64","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1681\/ASN.2012090903","article-title":"DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN","volume":"24","author":"Ozaltin","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.pcl.2022.07.006_bib65","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.kint.2020.01.045","article-title":"Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy","volume":"97","author":"Brocklebank","year":"2020","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.pcl.2022.07.006_bib66","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.pcl.2022.07.006_bib67","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2215\/CJN.01260212","article-title":"Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome","volume":"8","author":"Hofer","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pcl.2022.07.006_bib68","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3389\/fimmu.2019.01282","article-title":"Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: a nationwide database","volume":"10","author":"Puraswani","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.pcl.2022.07.006_bib69","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2016.99","article-title":"Anti-complement-factor H-associated glomerulopathies","volume":"12","author":"Durey","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.pcl.2022.07.006_bib70","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-0030-1262885","article-title":"Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS","volume":"36","author":"Dragon-Durey","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1016\/j.pcl.2022.07.006_bib71","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue","volume":"28","author":"Schwartz","year":"2013","journal-title":"J\u00a0Clin Apher"},{"issue":"5","key":"10.1016\/j.pcl.2022.07.006_bib72","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.pcl.2022.07.006_bib73","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00467-017-3612-9","article-title":"Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS","volume":"32","author":"Hackl","year":"2017","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"6","key":"10.1016\/j.pcl.2022.07.006_bib74","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.kint.2020.01.045","article-title":"Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland","volume":"97","author":"Brocklebank","year":"2017","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.pcl.2022.07.006_bib75","doi-asserted-by":"crossref","first-page":"152000","DOI":"10.1016\/j.imbio.2020.152000","article-title":"Anti-complement factor I antibody associated atypical hemolytic uremic syndrome - A new insight for future perspective!","volume":"225","author":"Govindarajan","year":"2020","journal-title":"Immunobiology"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395522000931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395522000931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:26:38Z","timestamp":1758475598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395522000931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0031395522000931"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2022.07.006","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemolytic-Uremic Syndrome in Children","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2022.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}